Copyright
©The Author(s) 2024.
World J Transplant. Jun 18, 2024; 14(2): 90382
Published online Jun 18, 2024. doi: 10.5500/wjt.v14.i2.90382
Published online Jun 18, 2024. doi: 10.5500/wjt.v14.i2.90382
Ref. | Study design | Study group | Post LT viremia n/N (%) | SVR12 | Time from transplant to start of DAA (d) |
Luckett et al[38], 2019 | Prospective | 55 HCV non-viremic candidates received HCV Ab+/NAT- LT, including 6 SLKT | 5/53 (9) | 4/5 SVR12 | NA |
Kwong et al[49], 2019 | Single-center, retrospective | 10 HCV non-viremic candidates received HCV NAT+ LT | 10/10 (100) | 10/10 SVR12 | Median 43 (IQR 20–59) |
Ting et al[50], 2019 | Single-center, retrospective | 6 seronegative candidates received HCV NAT+ LT, including 2 SLKT | 6/6 (100) | 3/6 SVR12 | Median 37 (range 9-74) |
1/6 completed DAA | |||||
2/6 ongoing DDA | |||||
Bethea et al[51], 2020 | Single-center, prospective | 14 HCV negative recipients, including 4 SLKT: | |||
9 received HCV NAT+ LT | 9/9 (100) | 9 SVR12 | Range 0-29 | ||
5 received HCV Ab+/NAT- LT | 1/5 (20) | NA | |||
Kapila et al[52], 2020 | Single-center, retrospective | 26 HCV negative recipients: | |||
20 received HCV NAT+ LT | 20/20 (100) | 11/20 SVR12 | Median 51 (range 19-121) | ||
3/20 completed DAA | |||||
5/20 ongoing DAA | |||||
1/20 pending insurance approval | |||||
6 received HCV Ab+/NAT- LT | 2/5 (40) | 1/5 SVR12 | |||
1/5 ongoing DAA | |||||
Anwar et al[34], 2020 | Single-center, prospective, matched cohort trial | 32 NAT- recipients received HCV NAT+ LT, including 7 SLKT | 31/31 (100) | 19/30 SVR12 | Median 47 (IQR 18-140) |
6/30 ETR | |||||
5/30 ongoing DAA | |||||
1/30 is yet to start treatment | |||||
Crismale et al[33], 2020 | Single-center prospective observational | 19 HCV negative recipients, including 4 SLKT: | |||
13 received HCV NAT+ LT | 13/13 (100) | 12/13 SVR12 | Median 42 (IQR 35-118) | ||
6 received HCV Ab+/NAT- LT | 0/6 (0) | ||||
Aqel et al[32], 2021 | Multicenter, prospective study | 34 HCV negative recipients, including 6 SLKT: | Median 27.5 | ||
20 received HCV NAT+ LT | 20/20 (100) | 20/20 SVR12 | |||
14 received HCV Ab+/NAT- LT | 0/14 (0) | ||||
Sobotka et al[37], 2021 | Single-center, retrospective | 42 HCV-seronegative recipients: | |||
21 received HCV NAT+ LT | 20/21 (95) | 15/15 (patients with data) SVR12 | Mean 38 | ||
21 received HCV Ab+/NAT- LT, including 1 SLKT | 2/21 (9.5) | 2/2 SVR12 | |||
Bohorquez et al[53], 2021 | Single-center, retrospective, case-control study | 61 HCV negative recipients, including 3 SLKT, received HCV NAT+ LT | 60/61 (98.3) | 51/56 SVR12 | Median 66.9 (IQR, 36-68.5) |
5/56 ongoing DDA when study published | |||||
Hudson et al[36], 2021 | Single-center, retrospective | 18 HCV negative recipients, including received HCV NAT+ LT | 18/18 (100) | 18/18 SVR12 | mean ± SD, 48 ± 23 |
Terrault et al[15], 2021 | Multicenter (6 US centers), prospective study | 13 HCV non-viremic candidates received HCV NAT+ LT | 13/13 (100) | 13/13 SVR12 | Median 7 (IQR 6-12) |
Nair et al[104], 2021 | Retrospective cohort | 23 HCV negative recipients received an HCV Ab+/NAT+ LT | 23/23 (100) | 23/23 SVR12 | Median 118 (IQR 46-129) |
Bova et al[35], 2022 | Single-center, retrospective | 29 HCV-negative recipients received HCV-viremic or HCV-seropositive LT, including 4 SLKT | 29/29 (100) | NA | Median 29 (range 0-84) |
- Citation: Hashem M, Medhat MA, Abdeltawab D, Makhlouf NA. Expanding the liver donor pool worldwide with hepatitis C infected livers, is it the time? World J Transplant 2024; 14(2): 90382
- URL: https://www.wjgnet.com/2220-3230/full/v14/i2/90382.htm
- DOI: https://dx.doi.org/10.5500/wjt.v14.i2.90382